Home＞ACADEMIA
Positioning of Abraxane and Anti-PD-1 Antibodies Will Be Focus of Interest in Revised Guidelines for Gastric Cancer(Mar.23.2016)
The Japanese Gastric Cancer Association (JGCA) is revising the guidelines for the treatment of gastric cancer. Evidence from a number of clinical trials to be announced going forward is expected to be reflected in the revised guidelines’ recommendations on chemotherapy. It plans to announce the revised guidelines in 2017, which would be the third year since their last revision ...
(LOG IN FOR FULL STORY)
-
- Japanese Society of Medical Oncology to Update I/O Guidelines in October Jul.18
- Hematologist Optimistic about New Drugs for AML Including SMO and BCL-2 Inhibitors as Well as FLT3 Inhibitors Jul.11
-
Doctors Need Solid Understanding of Hereditary Cancer When Prescribing Lynparza for Breast Cancer: Prof.
Jul.05
- Anti-TNF-α Antibody Treatment for Crohn’s Disease Costs 1.95 Million Yen per Patient Annually: Study Jun.27
- Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment Jun.26
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda(Jul.20)
- Takeda, Ovid Launching 3 New Studies for Rare Epilepsy Drug(Jul.20)
- Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard(Jul.20)
- Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources(Jul.20)
- Fuji Pharma Poised to Develop New Biosimilar in Women’s Health/Acute Care(Jul.19)
